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THEMATIC REVIEW SERIESLipoprotein metabolism in familial hypercholesterolemiaKévin Chemello1, Javier García-Nafría2,3, Antonio Gallo4,5, Cesar Martín6, Gilles Lambert1,*, and
Dirk Blom7
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University of Cape Town, Cape Town, South AfricaAbstract Familial hypercholesterolemia (FH) is one
of the most common genetic disorders in humans. It is
an extremely atherogenic metabolic disorder charac-
terized by lifelong elevations of circulating LDL-C
levels often leading to premature cardiovascular
events. In this review, we discuss the clinical pheno-
types of heterozygous and homozygous FH, the genetic
variants in four genes (LDLR/APOB/PCSK9/LDLRAP1)
underpinning the FH phenotype as well as the most
recent in vitro experimental approaches used to
investigate molecular defects affecting the LDL re-
ceptor pathway. In addition, we review perturbations
in the metabolism of lipoproteins other than LDL in
FH, with a major focus on lipoprotein (a). Finally, we
discuss the mode of action and efficacy of many of the
currently approved hypocholesterolemic agents used
to treat patients with FH, with a special emphasis on
the treatment of phenotypically more severe forms of
FH.
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Familial hypercholesterolemia (FH) is an inherited
metabolic disease associated with high levels of circu-
lating LDL-C and premature CVD (1). Heterozygous
familial hypercholesterolemia (HeFH) is a common
genetic disorder resulting from an autosomal dominant
or codominant inheritance pattern with an estimated
prevalence of 1 in 250 subjects in most countries.
However, the prevalence is much higher in regions or
localized populations with founder effects (2, 3). Ho-
mozygous familial hypercholesterolemia (HoFH) is
characterized by a much lower prevalence, around one
case in 160,000–300,000 subjects (4). In rare instances,
HoFH is transmitted as a recessive trait (5). Here, we
focus on the clinical phenotypes of FH, the genetic
variants at the origin of the phenotype as well as on the*For correspondence: Gilles Lambert, gilles.lambert@univ-reunion.
fr.
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gate molecular defects affecting the LDL receptor
(LDLR) pathway in FH. The perturbations of lipopro-
tein metabolism beyond LDL as well as the mode of
action and efficacy of the currently approved hypo-
cholesterolemic agents used to treat patients with FH
are also reviewed.CLINICAL PRESENTATION AND DIAGNOSIS
Untreated, FH frequently results in premature
atherosclerotic CVD (ASCVD), the first ASCVD in
HoFH often occurring in childhood or adolescence (6),
whereas patients with HeFH usually experience their
first ASCVD event in the third or fourth decade of life
(7). Lifelong exposure to high LDL-C levels has been
shown to be the main determinant of the increased risk
of ASCVD in patients with FH (3, 4, 8, 9). The coronary
territory is by far the most affected (10–12), but cere-
brovascular and/or peripheral artery diseases are also
seen in some patients with FH (13, 14).
A high untreated LDL-C is often the first clue alert-
ing clinicians to a possible diagnosis of FH. After
exclusion of secondary causes of hypercholesterolemia,
many clinicians use scoring systems that incorporate
both clinical and laboratory criteria to assist in the
diagnosis of FH. The Simon-Broome criteria algorithm
takes into account the proband total and LDL-C, the
presence of tendon xanthomata, the presence of a ge-
netic mutation, and a family history of ASCVD (7). The
Dutch Lipid Clinics Network Score is probably the most
well known of such scores. It considers the same criteria
with a more refined classification for LDL-C level
ranges as well as for family history of FH and/or pre-
mature ASCVD and genetic analyses (15). The Interna-
tional Classification of Diseases, Tenth Revision definition
algorithm takes into account LDL-C levels and the
eventual presence of a mutation in the index case pa-
tient and relatives. In a similar way, make earlyJ. Lipid Res. (2021) 62 100062 1
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diagnosis to prevent early deaths criteria take into ac-
count the proband age, his and/or her LDL-C, and the
closest parental degree of a confirmed affected relative
(16).
The association of common cardiovascular risk fac-
tors, such as male sex, smoking, hypertension and dia-
betes, as well as low HDL-C in patients with FH increases
exponentially the cardiovascular morbidity and mor-
tality and accounts for about one in four-to-five ASCVD
cases within this population (17, 18). Likewise, the pres-
ence of metabolic disorders such as insulin resistance in
obesity and diabetes has shown to further increase the
risk ofASCVD inFH.Theprevalence of obesity has been
reported at around 20% in several FH cohorts, whereas a
more variable estimation of type 2 diabetes has been
shown across the world, ranging from 1.75% to 25% (12,
19–22). Patients with FHhave been found in a number of
studies to exhibit lower prevalence of diabetes
compared with their unaffected siblings (23).
GENETICS AND FUNCTIONAL
CHARACTERIZATION OF FH
The genetic defects underlying FH reside either on
the LDLR, APOB, PCSK9, or LDLRAP1 genes and result in
reduced clearance of plasma LDL by the LDLR
pathway leading to lifelong elevations in circulating
LDL-C levels (Fig. 1).
The LDLR
In approximately 90% of the cases, FH results from
the presence of mutations in the LDLR gene itself (3,
24). More than 1,700 different LDLR mutations have
been described (25, 26). LDLR mutations can either
result in an absence of biosynthesis (class 1 defects),
preclude the maturation/transportation of the receptor
from the endoplasmic reticulum to the Golgi (class 2),
reduce the affinity of the receptor for LDL particles
(class 3), alter the internalization of the receptor/ligand
complex (class 4), or prevent normal recycling of the
LDLR back to the cell surface (class 5) (27) (Fig. 2).
The LDLR pathway was discovered in 1974 by Brown
and Goldstein. They showed that the high affinity of
125iodine-radiolabeled LDL for human dermal fibro-
blast was absent when fibroblasts were obtained from
patients with HoFH (1, 28). Since these pioneering
studies, novel approaches have been successfully
developed to determine LDLR activity and hence the
pathogenicity of LDLR genetic variants ex vivo. For
instance, lymphocytes isolated from patients carrying
LDLR variants and subsequently immortalized have
progressively replaced dermal fibroblasts when study-
ing LDLR function (29, 30). Primary lymphocytes can
alternatively be expanded in culture using either mi-
togens or CD3/CD28 dynabeads (31, 32). In addition,
LDLR expression can be enhanced by serum depriva-
tion or statin treatment (33, 34), thus facilitating the
assessment of LDLR expression by Western blot, as well2 J. Lipid Res. (2021) 62 100062as the characterization of LDLR activity by flow
cytometry using fluorescently labeled LDL (35). These
novel approaches yield qualitatively and quantitatively
similar results to those obtained in the past using
dermal fibroblasts and radiolabeled LDL. Labeling of
the LDLR with fluorescent antibodies and LDL parti-
cles with fluorescent dyes, respectively, allows the
determination of LDLR expression levels at the cell
surface and the assessment of LDL cellular binding at
4◦C as well as cellular uptake at 7◦C. Trypan blue is
used in these experiments to quench the fluorescence
of noninternalized LDL particles (35).
Nowadays,most LDLR functional studies can easily be
carried out with the LDLR-deficient Chinese hamster
ovary cell line ldlΔ7 transfected with plasmids allowing
the expression of LDLR variants (35, 36). Cellular LDLR
expression is assessed by Western blot, which allows the
detection of the LDLR precursor (120 kDa) and of the
mature receptor (160 kDa). LDLR cell surface expression
and LDLR activity (i.e., LDL binding and uptake) are
assessed by flow cytometry, as described above. In addi-
tion, confocal microscopy analyses permit the determi-
nation of most class-type defects of LDLR variants by
assessing the colocalization of the receptor with endo-
somal, lysosomal, and/or endoplasmic reticulum-
specific markers. A modified ELISA binding assay
measuring the affinity of LDLR variants for LDL par-
ticles is howevermore suited todetect a class 3 defect (37).
A class 5 defect can be determined by performing a
similar binding assay at the acidic pH found in endo-
somes (38). These in vitro approaches are easy to set up as
there is no need for clinical samples. They also allow
accurate determination of the mechanisms underlying
the pathogenicity of each LDLR variant, as they mimic
HoFH conditions that can be masked in heterozygous
states, in particular formildly pathogenic LDLRvariants.
Apolipoprotein B100
In approximately 5% of the cases, FH results from the
presence ofmutations on apolipoprotein B100 (apoB100),
the major protein component of LDL that serves as a
ligand for the LDLR (39). This condition is also named
familial defective apolipoprotein B (FDB) (Fig. 3). Only a
handful of APOB mutations causing FH have been re-
ported, and they are all located within (or in the vicinity
of) the LDLR binding region of apoB100 (26).
Initially, LDL binding and LDL uptake studies using
radiolabeled LDL isolated from patients with APOB
genetic variants were used to assess their pathogenicity
(39). Fluorescently labeled LDL isolated from patients is
now used to perform these assays (40, 41), either in
primary human lymphocytes or in cell lines expressing
wild-type LDLR, as described above. The U937 cell line
that derives from a histiocytic lymphoma has been
extremely helpful in that respect. U937 cells lack 3-
ketosteroid reductase, required for endogenous
cholesterol synthesis, and therefore require extracel-
lular cholesterol supply for proliferation (42). The
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Fig. 1. Schematic overview of the LDL receptor (LDLR) pathway. The extracellular domain of the LDLR binds to apolipoprotein
B100 (apoB100) of an LDL particle. The intracellular domain of the receptor interacts with its adaptor protein [LDLR adapter protein
1 (LDLRAP1)], allowing endocytosis of LDL particle into clathrin-coated vesicles. The LDL-LDLR complex reaches the endosome
where the acidic pH induces the dissociation of the complex. The receptor is recycled back to the cell surface, whereas the particle is
degraded in the lysosomal compartment. When proprotein convertase subtilisin kexin type 9 (PCSK9) is bound to the receptor, the
LDL-LDLR complex cannot dissociate, and the receptor ends up in the lysosome where it is degraded.proliferation rate of these cells in the presence of LDL
carrying wild-type or FDB variants is a measure of the
ability of the LDL to bind to the LDLR (38, 40, 41). A
modified ELISA binding assay using recombinant
LDLR for capture of wild-type or FDB LDL can also be
used (43).
Proprotein convertase subtilisin kexin type 9
In approximately 1% of cases, FH results from the
presence of “gain-of-function” (GOF) mutations onproprotein convertase subtilisin kexin type 9 (PCSK9)
(44). PCSK9 is a protein secreted by the liver. At the cell
surface, PCSK9 binds to the first epidermal growth
factor-like repeat homology domain of the LDLR. Af-
ter endocytosis, the affinity between the LDLR and
PCSK9 is much higher (as a result of the acidic pH
conditions of endosomes), and the interaction between
PCSK9 and LDLR locks the receptor in an extended or
“open” conformation (45) (Fig. 1). The failure of the
receptor to adopt a “closed” conformation in theLipoprotein metabolism in FH 3
Fig. 2. Assessment of LDL receptor (LDLR) class defects. The pathogenicity of LDLR variants results either from an absence of
biosynthesis of the receptor (class 1), a transport defect of the receptor from the endoplasmic reticulum to the Golgi (class 2), poor
binding of the receptor to LDL particles (class 3), an absence of receptor internalization (class 4), or failure to recycle back to the cell
surface (class 5).endosome precludes normal recycling to the plasma
membrane and targets the LDLR for lysosomal degra-
dation (Fig. 3). PCSK9 has also been shown to promote
LDLR decay via an intracellular route. Similar to LDLR
gene defects, PCSK9 GOF mutations lower the abun-
dance of the LDLR at the cell surface in many
different ways (46, 47). For instance, genetic variants on
PCSK9 can display either higher transcriptional activ-
ity, or resistance to cleavage by furin, or increased af-
finity for the LDLR.
The methodologies to characterize PCSK9 GOF vari-
ants are quite heterogeneous and rely on different4 J. Lipid Res. (2021) 62 100062approaches, such as immunocytochemistry, flow cytom-
etry, and biochemistry techniques (48–51). As for patients
with FDB, fibroblasts or lymphocytes from PCSK9 mu-
tation carriers should be evaluated to ascertain that their
LDLR is expressed normally and fully functional to rule
out any potentially undetected LDLR defect (40, 51).
Then, the synthesis, secretion, and LDLR inhibitory ef-
fects of PCSK9 variants can be comparatively assessed by
transfecting cell lines that do not endogenously express
PCSK9, such as human embryonic kidney 293 cells, with
wild-type or PCSK9 variant expression vectors. Intracel-
lular and secreted PCSK9 levels are determined by
Fig. 3. Molecular causes of familial hypercholesterolemia. Autosomal dominant hypercholesterolemia (ADH) is caused by muta-
tions either on the LDLR (ADH1), APOB (ADH2), or PCSK9 (ADH3) genes. Biallelic mutations on LDLRAP1 promote autosomal
recessive hypercholesterolemia (ARH).Western blot to assess the ratio of nonprocessed/pro-
cessed PCSK9 in cell extracts, the levels of secretion of
PCSK9 in the culture medium, and the ability of furin to
mediate the cleavage of secreted PCSK9, comparatively
for wild-type and PCSK9 variants. LDLR cell surface
expression and fluorescently labeled LDL uptake are
determined by flow cytometry as above.
Given that PCSK9 acts primarily as a secreted protein,
the extracellular activity ofwild-type andPCSK9variants
canbecomparatively assessedbyadding the recombinant
PCSK9 proteins in the culture medium of hepatoma cell
lines (e.g., HepG2) prior to measurement of cell surfaceLDLRexpression and fluorescent LDLcellularuptakeby
flow cytometry (47, 50–52). Another valuable parameter
that provides important information about PCSK9 vari-
ants is to measure their affinity for the LDLR at the cell
surface and in endosomes. This can be evaluated by solid-
phase immunoassay at pH 7.4 and 5.2, respectively, using
the recombinant LDLR ectodomain to capture PCSK9
(47, 51). Given that somePCSK9variants have been shown
to inhibit LDLR prior to secretion, this intracellular ac-
tivity can be assessed in human embryonic kidney 293
cells coexpressing the LDLR ectodomain and either wild-
type or PCSK9 variants. The amount of LDLRLipoprotein metabolism in FH 5
ectodomain secreted in the culture medium can be
assessed by Western blot and recapitulates the ability of
PCSK9 variants to impact the translocation of the LDLR
from intracellular compartments to the cell surface (47,
52).
The LDLR adaptor protein 1
The HoFH phenotype can also be caused by variants in
the LDLR adapter protein 1 (LDLRAP1) gene, but this
particular condition is an autosomal recessive disorder
known as autosomal recessive hypercholesterolemia
(ARH). Heterozygous carriers of LDLRAP1 mutations
present with normal circulating lipoprotein levels (53).
LDLRAP1 bridges the intracellular domain of the LDLR
with clathrin, an essential protein involved in the forma-
tion of endocytic vesicles and hence LDL cellular uptake
(Figs. 1 and 3).
Ex vivo investigation of ARH is not as straight-
forward as that of autosomal dominant hypercho-
lesterolemia. For instance, LDLRAP1 functionality
cannot be assessed in patient's dermal fibroblasts, as
the adaptor protein is not required for LDLR
endocytosis into clathrin-coated pits in this partic-
ular cell type (54–56). In contrast, LDLRAP1 is
essential for LDLR internalization into human lym-
phocytes and hepatocytes. The cellular assessment of
LDLRAP1 variants can therefore be performed in
ARH lymphocytes, where cell surface LDLR levels
are always much higher than in control lympho-
cytes, whereas fluorescent LDL uptake is signifi-
cantly reduced (57).
An extreme phenotypic variability
The clinical phenotype of patients with FH may vary
considerably. The extent of LDL-C elevation is the
most important determinant of phenotypic severity.
LDL-C elevation is not only related to a gene-dosage
effect (the presence of two mutations instead of one
is associated with a more severe phenotype) but also
depends on the functional impact of mutations. For
instance, LDLR mutations are usually described as
“null” (<2% of normal LDLR activity) or “defective”
(between 2% and 25% of normal activity) (4). Null
mutations correlate with the more severe forms of
HeFH. The following sequence of genotypes is associ-
ated with the most severe to mildest phenotypes: ho-
mozygosis for LDLR null mutations; compound
heterozygosis for LDLR null and LDLR-defective
mutations; homozygosis for LDLR-defective muta-
tions or LDLRAP1; homozygosis for defective APOB
or PCSK9 GOF mutations; and heterozygosis for LDLR
null mutations. The FH phenotype is also modulated
by other genetic and environmental factors, and pa-
tients with identical mutations also show marked
phenotypic variability. The mildest forms of HoFH
often overlap with more severe forms of HeFH; some6 J. Lipid Res. (2021) 62 100062HeFH in turn may overlap with more severe forms of
polygenic FH.
LIPOPROTEIN METABOLISM IN FH BEYOND
LDL
Although impaired LDLR function, and thus
decreased clearance of LDL from the circulation, is the
hallmark of FH, decreased LDLR function does not
entirely explain the dyslipidemia seen in FH. The
mutational diversity in these four genes variably mod-
ulates the LDLR pathway and thereby determines the
heterogeneity of LDL-C levels found in FH. Although
the LDLR is expressed in many cell types, the liver is by
far the primary site of LDL cellular uptake, which is
evidenced by the report of an accidental transmission
of a severe FH phenotype to a previously normolipemic
liver transplant recipient (58). Compared with LDL, the
circulating levels of other lipoproteins are not or mildly
affected in FH, with some exceptions in particular
when a metabolic syndrome is present. However, the
levels of lipoprotein (a) [Lp(a)] appear to be increased in
patients with FH compared with the general
population.
Lipoprotein (a)
Lp(a) is an atherogenic lipoprotein consisting of an
apolipoprotein (a) [apo(a)] protein covalently tethered
to the apoB100 of an LDL particle. Apo(a) is encoded by
the LPA gene and presents a highly repetitive structure,
the kringle IV2 domain present in 1 to more than 40
copies per allele. The size of apo(a) explains up to 70%
of Lp(a) variance in humans: the number of KIV2 do-
mains on apo(a) is inversely proportional to Lp(a)
plasma levels. The initial studies that have investigated
Lp(a) in FH have not yielded conclusive results, given
the wide variation of Lp(a) resulting from the size
polymorphism of apo(a) (59). However, the assessment
of FH and non-FH siblings with apo(a) isoforms iden-
tical by descent has clearly demonstrated that Lp(a) is
approximately twice higher in patients with FH than in
their nonaffected family members (59). FH homozy-
gotes with two nonfunctional LDLR alleles also display
2-fold higher Lp(a) levels than their heterozygote rela-
tives (60). Likewise, patients with FDB have higher Lp(a)
than non-FDB family members (61), and PCSK9 GOF
mutation carriers also similarly display higher Lp(a)
than non-FH controls (62). Although these combined
results appear to advocate for a direct role of the LDLR
in mediating Lp(a) plasma clearance, no such conclu-
sion was drawn from these studies by their authors.
For instance, in vitro, the binding and cellular uptake
of Lp(a) is reduced in primary HoFH dermal fibroblasts
totally lacking the LDLR in some studies but not in
others (63, 64). We recently reported that the cellular
uptake of Lp(a) was similar in primary lymphocytes
isolated from patients with HoFH and healthy donors
(65). In vivo, the pharmacological modulation of the
LDLR using PCSK9 inhibitors did significantly affect
neither the fractional catabolic rate (FCR) of Lp(a) in
nonhuman primates (66) nor the hepatic capture of
fluorescently labeled Lp(a) in liver humanized mice (65).
In humans, the FCR of Lp(a) was not statistically
different between control individuals and HeFH or
HoFH patients separately, but compared with non-FH
controls, the FCR of Lp(a) was significantly reduced
when combining all patients with FH (60, 67). In patients,
enhancing LDLR function using PCSK9 inhibitors in
monotherapy nonsignificantly increased the FCR of
Lp(a) in one study (68) but reduced it in another study
(69). Importantly, unlike PCSK9 inhibitors, statins that
also increase the abundance of the LDLR significantly
raise Lp(a) in humans (70).
Apo(a) isoforms have been reported to vary from 300
to 800 kDa in size (71), and recombinant apo(a) (con-
taining 17 kringle IV domains) has been shown to
extend up to 800 Å into solution. Hence, to gain insights
into the determinants of Lp(a) clearance, Lp(a) has been
subjected to diverse structural studies over the years,
however, without reaching a consensus. Atomic force
microscopy suggested that apo(a) is anchored to the
LDL by the N and C terminus. Small-angle X-ray scat-
tering suggested that apo(a) locates to the surface and
wraps around the LDL particle (72), and studies using
electron microscopy concluded that the bulk of apo(a)
extends away from the LDL surface (73). To visualize
Lp(a) particles in a near-native environment and at
higher resolution, we recently purified LDL and Lp(a)
particles and subjected them to cryogenic electron mi-
croscopy. The 2D images of these lipoproteins were





Fig. 4. 3D reconstruction of lipoprotein (a) [Lp(a)] particles by cr
vitrified using glow discharged Cu grids 1.2/1.3, and an FEI Vitrobot
50e−/A2). Images were motion and contrast transfer function co
reconstruction, 3D classification, and refinement. Raw micrographs
erages displayed weak density protrusions from the surface of tho
rowheads). A 3D reconstruction (with 42,247 particles at a 15 Å resol
(in red) corresponding to the insertion point of apo(a) (panel C).tridimensional model (74). Unlike LDL, Lp(a) displays a
weak density protrusion from the surface correspond-
ing to the apo(a) moiety (Fig. 4B). The 3D model shows
additional cryogenic electron microscopy density on
Lp(a) particles corresponding to the insertion point of
apo(a) (Fig. 4C). This feature was absent from human
LDL (75). Apo(a) seems to adopt a disordered confor-
mation, but it clamps to apoB100 in the vicinity of its
LDLR binding site (75), which may cause steric hin-
drance preventing proper Lp(a) uptake by the LDLR.
The fact that Lp(a) is higher in patients with FH has
recently been challenged by two independent studies.
In 46,200 individuals from the Copenhagen General
Population Study in whom Lp(a) was measured, mean
Lp(a) concentrations were 23 mg/dl in individuals un-
likely to have FH, 32 mg/dl in subjects with possible FH,
and 35 mg/dl in those with probable or definite FH,
based on the Dutch Lipid Clinics Network diagnostic
criteria (76). However, after adjusting LDL-C levels for
Lp(a) cholesterol to more accurately assess the FH sta-
tus, those values were similar at 24, 22, and 21 mg/dl,
respectively. Similar observations were made when us-
ing the make early diagnosis to prevent early deaths or
Simon-Broome FH diagnostic criteria (77) as well as in
the British Columbia FH cohort using the Dutch Lipid
Clinics Network criteria (78), indicating that a substan-
tial proportion of patients clinically diagnosed with FH
are in fact hyperlipoprotein(a)emic and not genuine
FH.
In the British Columbia FH cohort, Lp(a) was found
higher than in the general reference population, but
there was no difference in Lp(a) plasma levels between
carriers of LDLR or APOB pathogenic variants
compared with noncarriers (78). The authors ratherFront
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yogenic electron microscopy. Lp(a) particles (0.8 mg/ml) were
IV and 900 micrographs were collected (1.65 Å/pixel, total dose
rrected following particle picking, 2D averaging, ab initio 3D
showed characteristic LDL-like particles (panel A), and 2D av-
se particles corresponding to their apo(a) moieties (panel B, ar-
ution) showed additional cryogenic electron microscopy density
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found that elevated Lp(a) levels in FH were linked to a
2-fold higher prevalence of a specific single nucleotide
polymorphism (rs10455872) on the LPA gene associated
with an average 64 mg/dl increase in circulating Lp(a)
levels (79) in that cohort compared with reference
populations, suggesting that there may be an ascer-
tainment bias in the association between FH and
elevated Lp(a) (78). They further investigated this hy-
pothesis using whole exome sequencing by identifying
221 “true” FH patients (i.e., with pathogenic mutations
on the LDLR, APOB, or PCSK9 genes) out of 37,486 in-
dividuals in the UK Biobank, without prior knowledge
of their clinical history. As anticipated, these 221 in-
dividuals had significantly higher LDL-C and apoB100
plasma levels than the 37,265 non-FH individuals, but
both groups displayed similar circulating Lp(a) con-
centrations (78). It therefore appears that the pheno-
typic determination of FH based on scores without
genotyping for a pathogenic allele on LDLR, APOB, or
PCSK9 or without adjusting LDL-C for Lp(a) logically
enriches the FH population with patients with hyper-
lipoprotein(a)emia.
These novel insights therefore cast a doubt on the
consensus that Lp(a) is elevated in FH. But given that
elevated Lp(a) can only accelerate the occurrence and
aggravate the magnitude of cardiovascular events in
patients already at very high risk, it cannot be empha-
sized enough that Lp(a) concentrations should be sys-
tematically measured in FH not only for diagnostic
accuracy but also to better manage an apparent resis-
tance to statins in these patients.
High density lipoproteins
HDL-C has been widely explored in FH. Equivocal
results have been found regarding HDL-C levels in FH,
some studies finding no difference with non-FH pop-
ulations, others finding lower levels (80–82). Some
studies have focused on HDL particle size and showed
that HDL particles are smaller in FH and thus more
atherogenic (80). For instance, impaired reverse
cholesterol transport has been shown to further in-
crease cardiovascular risk (83) in both HeFH and HoFH,
further underlining that HDL functionality, rather
than mere cholesterol content of HDL, better reflects
the atheroprotective functions of HDL particles (84).
Thus, the centripetal transport of cholesterol from pe-
ripheral cells to feces appears altered in FH. The efflux
of cellular cholesterol to HDL is apparently lower when
HDL are isolated from patients with FH, leading to
decreased esterification by LCAT, which is associated
with an increased risk of ASCVD in a study conducted
in 71 patients with HeFH and 66 normolipidemic in-
dividuals (85). The established antioxidant and anti-
inflammatory properties of HDL also appear to be
impaired in FH (86). Likewise, kinetics studies using
stable isotope have shown a reduced turnover for
apolipoprotein A1 (apoA1; both production and catab-
olism) in patients with FH (87). In HoFH, the impact of8 J. Lipid Res. (2021) 62 100062LDLR expression on HDL function has not been
clearly established. ApoA1 FCR is reduced in HoFH
suggesting an impaired transfer of cholesteryl esters to
LDL. In addition, HDL size and composition appear
impaired in subjects with FH and parallel an increased
transfer of cholesteryl ester to LDL.
Triglycerides
The presence of low HDL concomitant with high
triglyceride (TG) levels usually mirrors an impaired
metabolic status (e.g., insulin resistance, central obesity,
diabetes). Thus, markers of insulin resistance such as
low adiponectin levels, further increase the cardiovas-
cular risk associated with FH (88). In this case, post-
prandial dyslipoproteinemia characterized by a hepatic
overproduction of TGs as well as an impairment in the
catabolism of TG-rich lipoproteins (TRLs) may be
observed. Apart from the additive effect of the con-
comitancy of cardiometabolic risk factors in FH, the
genetic defect underlying this condition may by itself
impact on the metabolism of TRLs. Interactions be-
tween TRLs and the LDLR have been shown in animal
models. Defects in LDLR function appears to also alter
the interaction between apolipoprotein B (apoB) and
apolipoprotein E, present on TRLs, and the LDLR thus
determining a predisposition to postprandial hyperlip-
idemia in FH as well (89, 90).
In addition, the impairment of LDLR expression
appears to influence the hepatic secretion of apoB-
containing lipoproteins. Thus, patients with HoFH and
animal models totally lacking LDLR activity display
higher VLDL, intermediate density lipoprotein, and
apoB production rates than non-FH individuals
(reviewed in detail elsewhere (91, 92)). Similarly, PCSK9
GOF mutation carriers exhibit higher production rates
of apoB-containing lipoproteins (93). For this reason,
PCSK9 was also hypothesized to induce changes in
ApoB48 metabolism in subjects with FH, but a study
conducted in patients with 118 HeFH and 6 HoFH failed
to establish a relationship between ApoB48 circulating
levels and PCSK9 (94).
Given the aforementioned important aspects of
impaired lipoprotein metabolism beyond LDL, patients
with FH should clearly be monitored for HDL-C, TGs,
apoA1, and apoB100 plasma levels more frequently.
LIPID-LOWERING TREATMENTS
In FH, elevated levels of LDL-C are the main driver
of atherosclerosis, and lowering LDL-C is the primary
focus of pharmacological therapy. The cholesterol-year
score integrates the exposure of the vasculature to
cholesterol over time. The more severe the baseline
LDL-C elevation is, the earlier and more intensive
therapy is required (95). Generally, treatment should be
commenced at the age of 8–10 years and immediately
following diagnosis in children with HeFH and HoFH,
respectively (3, 4, 96). The ultimate goal of treatment is
to prevent clinical manifestations of ASCVD in patients
with FH, rather than only delaying the first cardiovas-
cular event.
There are no double-blind placebo-controlled car-
diovascular outcome trials specifically targeting pa-
tients with FH, and it is unlikely that there ever will be.
However, multiple observational studies support the
benefit of treating patients with FH. In a retrospective
study of a large cohort of Dutch patients with FH seen
either before or after the availability of statin-based
lipid-lowering therapy (using January 1990 as the cut-
off date), the risk of a first cardiovascular event was
76% lower in patients with FH treated with a statin (97).
In another retrospective review of patients with HeFH,
moderate- to high-intensity statin therapy lowered the
risk for CAD and mortality by 44% (98). Similarly,
treatment initiation in children with HeFH slowed the
rate of progression in carotid intima media thickness
and was associated with a marked improvement in
cardiovascular event free survival compared with their
affected parent (99). In patients with HoFH, access to
statin therapy was also associated with improved sur-
vival, with on-treatment LDL-C being the major deter-
minant of outcome (9, 100).
Conceptually, there are three main mechanisms by
which circulating LDL-C levels can be reduced. LDL
clearance can be increased either by upregulating the
number of LDLRs on the cell surface or by mechan-
ically removing circulating LDL through lipid apher-
esis or plasma exchange. Lipid apheresis will not be
discussed further, as it is likely that the introduction of
novel therapies will continue to diminish the role of
and requirement for such procedures. Decreasing the
hepatic production and secretion of apoB-containing
lipoproteins (primarily VLDL) also ultimately lowers
circulating LDL. Most lipid-lowering therapies
routinely used in the management of FH act pre-
dominantly by upregulating LDLR expression. These
therapies work well in patients with HeFH who have
one wild-type LDLR allele. In patients with HoFH, the
efficacy of treatments that act by upregulating LDLR
is determined in part by the residual LDLR function,
and most patients with HoFH are not as responsive to
such therapies as patients with other forms of
hypercholesterolemia.
Statins
Statins are the backbone of lipid-lowering therapy in
patients with FH. Given their high baseline LDL-C, most
adult patients require high doses of high-intensity sta-
tins (atorvastatin 40–80 mg/d or rosuvastatin
20–40 mg/d). Atorvastatin (80 mg/d) reduced LDL-C
levels by 46–57% in patients with HeFH (101, 102).
When rosuvastatin (40 mg/d) and atorvastatin (80 mg/
d) were compared directly in a blinded and randomized
forced titration study in patients with HeFH, they
lowered LDL-C by 53.9% and 50.4%, respectively (103).
Statin dosing should be individualized taking intoaccount age, cardiovascular status, and LDL-C goal, as
well as concomitant medication and tolerability. Statins
are generally less effective in patients with HoFH, but
the responses are highly variable. Patients with HoFH
with biallelic LDLR null mutations often, but not always,
fail to respond to such treatments (104, 105).
Ezetimibe
Ezetimibe inhibits the absorption of cholesterol and
phytosterols by enterocytes in the jejunal brush border
by blocking the action of Niemann-Pick C1-Like 1 pro-
tein (106). Ezetimibe may also reduce biliary cholesterol
reabsorption by hepatocytes through its interaction
with Niemann-Pick C1-Like 1 protein in biliary canal-
iculi. Ultimately, ezetimibe depletes the hepatic steroid
pool resulting in the upregulation of LDLR expression.
In the Effect of Ezetimibe Plus Simvastatin Versus
Simvastatin Alone on Atherosclerosis in the Carotid
Artery trial, 720 patients with HeFH were randomized
either to simvastatin (80 mg daily) with ezetimibe (10 mg
daily) or simvastatin (80 mg daily) only following a
single-blind 6-week placebo run-in period. The
observed LDL-C reductions were −55.6% and −39.1%,
respectively (107). In a study of patients with HoFH
taking atorvastatin or simvastatin (40 mg) at baseline,
randomization was either to uptitration of statin to
80 mg daily, addition of ezetimibe (10 mg daily) to an
unchanged statin dose, or addition of ezetimibe (10 mg
daily) and uptitration of the statin to 80 mg daily. LDL-
C decreased by 6.7% with statin uptitration only, while
addition of ezetimibe to any statin dose decreased LDL-
C by 20.7%. Unfortunately, the study was not able to
explore ezetimibe response as a function of residual
LDLR function (108).
PCSK9 inhibitors
Given its established role as a major inhibitor of the
LDLR, PCSK9 has become a prime therapeutic target to
lower LDL-C (45, 109). Currently, the two main ap-
proaches to decreasing the concentration of PCSK9 in
the circulation are binding PCSK9 with fully human
monoclonal antibodies (alirocumab or evolocumab) or
inhibiting the hepatic synthesis of PCSK9 with a small
interfering RNA such as inclisiran.
Alirocumab and evolocumab when added to preex-
isting lipid-lowering therapy in patients with HeFH
lower LDL-C by an additional 50–60% (110, 111). With
evolocumab, 63% (420 mg once a month) and 68%
(evolocumab 140 mg once every 2 weeks) of patients
were able to achieve LDL-C values below 1.8 mmol/l
(111). The corresponding figures for alirocumab are
59.8% (Odyssey FH I) and 68.2% (Odyssey FH II) (110). In
the Odyssey High FH study, which only enrolled pa-
tients with a baseline LDL-C above 4.1 mmol/l, 32.4% of
patients lowered their LDL-C to 1.8 mmol/l or below
(112). PCSK9 inhibition with monoclonal antibodies thus
allows the majority of patients with HeFH to reach the
<1.8 mmol/l LDL-C target for secondary prevention,Lipoprotein metabolism in FH 9
although only a minority are able to reach the current
target of <1.4 mmol/l for secondary prevention pa-
tients at very high risk of recurrent events. Monoclonal
antibodies directed against PCSK9 are nowadays
considered standard of care for patients with HeFH
unable to reach target with statins ± ezetimibe,
although funding difficulties still limit access in many
parts of the world. In HeFH, the response to PCSK9
monoclonal antibodies is not influenced by the impact
of the underlying LDLR mutation on LDLR function
(residual or no residual activity) (111). This is because in
patients with HeFH, upregulation of the wild-type
LDLR allele likely accounts for most LDL lowering
with a much smaller contribution from the mutated
LDLR. However, individual responses to therapy may
still differ markedly, even in individuals with identical
mutations. The effect of PCSK9 inhibition with
monoclonal antibodies on LDL-C in HoFH is even more
variable. In the Rutherford 2 study, which enrolled
patients with a clinical diagnosis of HeFH, 7 of the 331
participants were unexpectedly found to be genetic
homozygotes or compound heterozygotes. Although
the mean baseline LDL-C in these patients [5.3 mmol/l
(SD 2.8)] was moderately higher than that of patients
with HeFH with receptor-negative [4.4 mmol/l (1.3)] or
receptor-defective mutations [3.9 mmol/l (1.0)], the
LDL-C reductions at week 12 ranged from 48% (range,
38–64%) for evolocumab 420 mg once a month to 68%
(range, 40–82%) for evolocumab 140 mg every 2 weeks.
These responses are very comparable to those seen in
HeFH receptor-negative patients; 61% reduction with
evolocumab 140 mg every 2 weeks and 55% with evo-
locumab 420 mg administered monthly (111). Contrast-
ing with this, the two receptor-negative patients
enrolled in the Trial Evaluating PCSK9 Antibody in
Subjects With LDL Receptor Abnormalities (TESLA)
part A proof-of-concept study failed to respond to
evolocumab despite plasma PCSK9 being lowered by
more than 90% (113). Subsequently, the TESLA part B
study confirmed the importance of residual LDLR
function; patients with defective/defective mutation
status had an overall better response (−31.8%; 95%
confidence interval, −44.9 to −18.8) than patients with a
defective/negative status (–21.0%; 95% confidence in-
terval, –30.7 to –11.2) (114). The negative/negative pa-
tient in this study also showed no response to
evolocumab. Once again, large variations in individual
responses were seen, even in patients with two identical
mutations. The TESLA part B study included eight
patients who were genetic homozygotes for the c.681C
> G LDLR mutation. The range of LDL-C reduction
with evolocumab was 7.1–56.0% and correlated nega-
tively with the number of LDLR expressed on their
lymphocytes (115). Overall, monoclonal antibodies to
PCSK9 reduce LDL-C by about half as much in ho-
mozygous compared with heterozygous patients. Re-
sidual LDLR functionality (determined by the type of
mutation) and LDLR expression at the cell surface10 J. Lipid Res. (2021) 62 100062(determined by multiple factors) are important pre-
dictors of response.
Inclisiran lowered LDL-C by 39.7% (−47.9% differ-
ence from placebo) in 482 patients with a clinical
diagnosis of HeFH. Next-generation sequencing of the
four genes linked to FH identified 32 patients with
either double HeFH, compound HeFH, or true HoFH.
Baseline LDL-C in these patients was 3.9 mmol/l,
somewhat lower than the baseline LDL-C in patients
with definite pathogenic LDLR variants. The mean
placebo-corrected LDL-C reduction in patients with two
variants was 41.2%. LDL-C reductions achieved in pa-
tients with pathogenic, probably pathogenic, or variants
of unknown significance were −46.0%, −48.3%,
and −42.3%, respectively. Among patients with no
identified causative mutation, the mean LDL-C reduc-
tion was 59.2% (116). Although LDLR mutations were
classified somewhat differently in this study than in the
Rutherford 2 study, which assessed functional impact
(defective/negative) rather than the certainty of path-
ogenicity (pathogenic/probably pathogenic), both trials
support the notion that in HeFH the type of mutation is
of secondary importance in determining treatment
response. The efficacy of inclisiran in patients with
clinically diagnosed HoFH is likely to be similar to that
of the monoclonal antibodies directed against PCSK9.
Thus far, only the results of a small proof-of-concept
study are available. In this study, inclisiran lowered
LDL-C by 17.5–37.0% in three of four homozygous pa-
tients at day 180. The fourth patient not only failed to
respond to inclisiran but also had a history of minimal
responses to alirocumab and evolocumab.
Mipomersen and lomitapide
Both mipomersen and lomitapide inhibit the pro-
duction of apoB-containing lipoproteins and are
therefore effective even in patients with no residual
LDLR function. Mipomersen is an antisense oligonu-
cleotide that binds the mRNA for apoB100, leading to
its degradation and decreased hepatic synthesis of
VLDL. Lomitapide inhibits microsomal TG transfer
protein in the endoplasmic reticulum of enterocytes
and hepatocytes reducing both chylomicron and VLDL
production. Although both drugs are effective in pa-
tients with HeFH, their use is restricted to patients with
HoFH because of their potential for significant hepatic
toxicity. Mipomersen and lomitapide reduced LDL-C
by a mean of 24.7 and 40% (intention-to-treat analysis)
in their pivotal HoFH trials, respectively (117, 118). In-
creases in hepatic fat, with the development of hepatic
steatosis in some patients are intrinsic to the mechanism
of action of both drugs. Further research into the risk
of hepatic steatosis progressing to steatohepatitis,
fibrosis, and ultimately cirrhosis is ongoing. Adverse
effects specific to each drug include injection site re-
actions and flu-like symptoms for mipomersen.
Discontinuation rates were also high in the long-term
extension studies of mipomersen. Lomitapide
commonly causes gastrointestinal side effects, such as
nausea, flatulence, and diarrhea. These adverse effects
are most commonly seen early in treatment and can be
mitigated by slow-dose titration and institution of a low-
fat diet. Lomitapide remains a useful additional thera-
peutic option in homozygous patients who fail to
respond adequately to statins, ezetimibe, and PCSK9
inhibition but should only be prescribed by physicians
experienced in its use and willing to perform the
mandated regular monitoring of hepatic function.
Evinacumab
Evinacumab is a monoclonal antibody directed
against angiopoietin-like 3 (ANGPTL3). ANGPTL3 is
an inhibitor of endothelial and lipoprotein lipases. Loss-
of-function mutations in ANGPTL3 cause familial
combined hypolipidemia, a condition first identified in
the small Italian town of Campodimele and character-
ized by low levels of both apoB- and apoA1-containing
lipoproteins (119). In a trial of patients with refractory
hypercholesterolemia, defined as an LDL-C of greater
than 1.8 mmol/l or greater than 2.6 mmol/l for those
with or without clinical atherosclerotic disease despite
treatment with maximally tolerated statin (with or
without ezetimibe) and a PCSK9 monoclonal antibody,
evinacumab given in varying doses either subcutane-
ously or intravenously reduced LDL-C in a dose-
dependent manner by 24.2–56.0% compared with pla-
cebo. In this trial, 72% of patients had FH (120).
In patients with HoFH, evinacumab reduced LDL-C
by 47.1% (49% placebo corrected) with a numerically
slightly greater response (−53.5%) in patients with less
than 2% of residual LDLR activity (121). Evinacumab
had no effect on LDLR activity in lymphocytes from
patients with HoFH, which remained similarly low in
lymphocytes taken before and after evinacumab
treatment (122). Derepression of endothelial lipase by
inhibiting ANGPTL3 improves VLDL processing,
generating VLDL remnants with reduced size and
lipid content. These remnant particles are efficiently
removed from the circulation by redundant remnant
receptors. LDL-C decreases independently from
LDLR activity as the production of LDL particles is
reduced (123).
ω-3 fatty acids
Although FH is characterized by high LDL-C, LDLR
mutations may also impair the clearance of TRLs,
increasing the concentration of remnant lipoproteins
particularly in the postprandial state. Remnant lipo-
proteins are atherogenic and may also contribute to
cardiovascular risk in patients with FH (89, 124, 125).
Daily supplementation with 4 g of ω-3 fatty acid ethyl
esters (46% eicosapentaenoic acid and 38% docosahex-
aenoic acid) during an 8-week open-label study reduced
fasting TGs (−20%), apoB (−8%), VLDL-apoB-100
(−26%), and apoB-48 (−36%) in 20 intensively treated
(mostly high-dose statins and ezetimibe) patients withHeFH. Postprandial remnant exposure was also
reduced (total VLDL-apoB-100 area under curve −26%)
(126). Although treatment with ω-3 fatty acids consis-
tently reduce TRLs in clinical studies, most studies have
not been able to demonstrate a reduction in cardio-
vascular outcomes. Cardiovascular outcomes were
reduced in the JELIS (Japan EPA Lipid Intervention
Study) and REDUCE-IT (Reduction of Cardiovascular
Events with Icosapent Ethyl-Intervention Trial), both of
which supplemented patients with eicosapentaenoic
acid only rather than utilizing a mixture of ω-3 fatty
acids. LDL-C had to be higher than 4.4 mmol/l or lower
than 2.59 mmol/l for inclusion into JELIS and
REDUCE-IT, respectively (127, 128). Concomitant lipid-
lowering therapy was generally more intense in
REDUCE-IT, which was published in 2019 compared
with the JELIS study, which was published in 2007.
Although there is no direct evidence of benefit of
treatment with ω-3 fatty acids in patients with FH spe-
cifically, treatment with 2 g of icosapent ethyl twice
daily should be considered in patients with adequately
controlled LDL-C and residual hypertriglyceridemia. If
LDL-C is not at target, further options to control LDL-C
(see below) should be considered first.CONCLUSIONS
With modern lipid-lowering therapies, most patients
with HeFH can achieve or come close to their LDL-C
target. Earlier and more consistent treatment of
HeFH from childhood should also reduce the need for
treating to the extremely low targets required for pa-
tients with established CVD. For patients with HoFH,
the largest breakthrough has come from therapies that
bypass the LDLR, enabling clinicians to treat all patients
with HoFH irrespective of their genotype with lipo-
protein apheresis as last treatment option.
But even if LDL-C levels can now be starkly reduced
in almost all patients with FH by combining statins,
ezetimibe, PCSK9 inhibitors, and eventually apheresis,
one hurdle still remains for patients with FH who
concomitantly display elevated Lp(a) levels. No doubt
that drugs inhibiting apo(a) expression that are
currently into development will prove instrumental in
that respect.
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Klingenberg, R., Schmied, C. M., Cornuz, J., Muller, O., Vogt, P.,
Jüni, P., Matter, C. M., Windecker, S., Lüscher, T. F., Mach, F., et al.
(2015) Prevalence and management of familial hyper-
cholesterolaemia in patients with acute coronary syndromes.
Eur. Heart J. 36, 2438–2445
11. Amor-Salamanca, A., Castillo, S., Gonzalez-Vioque, E., Domi-
nguez, F., Quintana, L., Lluís-Ganella, C., Escudier, J. M., Ortega,
J., Lara-Pezzi, E., Alonso-Pulpon, L., and Garcia-Pavia, P. (2017)
Genetically confirmed familial hypercholesterolemia in pa-
tients with acute coronary syndrome. J. Am. Coll. Cardiol. 70,
1732–1740
12. De Backer, G., Besseling, J., Chapman, J., Hovingh, G. K., Kas-
telein, J. J. P., Kotseva, K., Ray, K., Reiner, Ž., Wood, D., De
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